The military prosecution filed an indictment Sunday against Kamal Khatib, head of the Nur a-Shams terror cell in Judea and Samaria, for the July 2024 bombing that killed Reserve Sgt. Yehuda Geto, according to the IDF Spokesperson. The indictment details that the bomb was remotely detonated via a cell phone from a room in the Bal'a neighborhood, causing the security vehicle to overturn and ejecting Geto, who was killed. Khatib is charged with causing death with intent (equivalent to murder), attempted murder, leading an illegal association, trading in military equipment, and planting a bomb. The military court ordered him remanded until the end of proceedings.
At 10:05 Jerusalem on Monday, the military prosecution filed an indictment against Kamal Khatib, head of the Nur a-Shams terror cell, for the July 1, 2024 bombing that killed Reserve Sgt. Yehuda Geto. The initial report, citing N12, noted that Khatib was charged with causing death with intent and managing a terror organization. Shortly after, The Zioneer reported that the indictment detailed the remote detonation of a roadside bomb via a cell phone from a room in the Bal'a neighborhood of Tulkarm, causing the security vehicle to overturn and ejecting Geto, who was killed. Another person was wounded in the chest and head.
Later, the IDF Spokesperson released further details, confirming the indictment and adding that Khatib is also charged with leading an illegal association, trading in military equipment, and planting a bomb. The military court ordered him remanded until the end of proceedings. The evolution of reports shows the progression from a single news source to official military confirmation.
The Nur a-Shams cell operates in the Tulkarm area of Judea and Samaria. As The Zioneer has reported, the cell has been responsible for numerous attacks against Israeli forces. The indictment represents a significant step in prosecuting the leadership of the cell.
The court proceedings are ongoing. It remains to be seen whether additional suspects will be charged or if further details about the cell's operations will emerge during the trial.
3 developments
Source and signal
- Open-source intake